Related Experiment Video

Updated: Apr 22, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K

4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression

Ryosuke Tamura1, Yoshihito Yokoyama2, Hidemi Yoshida3

  • 1Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan. tam1122@cc.hirosaki-u.ac.jp.

Journal of Ovarian Research
|October 12, 2014
PubMed
Abstract

Insights

4-Methylumbelliferone (4-MU) shows antitumor effects in ovarian cancer by inhibiting cell proliferation and significantly decreasing thymidine phosphorylase (TP) expression, prolonging survival in a rat model.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • 4-Methylumbelliferone (4-MU) is a hyaluronan (HA) synthesis inhibitor with known antitumor properties.
  • Its specific effects and mechanisms in ovarian cancer remain under-investigated.

Purpose of the Study:

  • To investigate the antitumor effects of 4-MU on ovarian cancer.
  • To elucidate the underlying mechanism of action of 4-MU in ovarian cancer.

Main Methods:

  • Utilized the HRA human ovarian serous adenocarcinoma cell line for in vitro and in vivo studies.
  • Assessed cell proliferation, migration, and invasion using standard assays.
  • Quantified mRNA expression of key genes including HA synthase (HAS), CD44, VEGF, and thymidine phosphorylase (TP) via qRT-PCR.

Main Results:

  • 4-MU significantly inhibited ovarian tumor growth and prolonged survival in a rat peritoneal carcinomatosis model.
  • In vitro, 4-MU demonstrated dose-dependent inhibition of HRA cell proliferation but did not impact invasion or migration.
  • A significant decrease in thymidine phosphorylase (TP) mRNA expression was observed following 4-MU treatment.

Conclusions:

  • 4-Methylumbelliferone (4-MU) exhibits significant antitumor activity against ovarian cancer.
  • The primary mechanism appears to be the suppression of thymidine phosphorylase (TP) expression, contributing to reduced tumor growth and improved survival.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

9.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K